Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia

A Retrospective Analysis

Perini, Giulia MD*,†; Cotta Ramusino, Matteo MD*,†; Sinforiani, Elena MD*; Franciotta, Diego MD; Trifirò, Giusppe MD§; Ceroni, Mauro MD; Costa, Alfredo MD*,†

Alzheimer Disease & Associated Disorders: July–September 2019 - Volume 33 - Issue 3 - p 282–284
doi: 10.1097/WAD.0000000000000289
Brief Reports
Buy

The use of biomarkers has recently supported the association between Alzheimer disease (AD) pathology and the logopenic variant of primary progressive aphasia (PPA). We aim to investigate possible differences in cerebrospinal fluid (CSF) biomarker concentrations in the three PPA variants, and to assess any agreement between CSF biomarkers and (18)F-florbetapir PET. A group of 10 PPA were retrospectively enrolled. Patients with logopenic variant (lvPPA) showed different levels of Aβ1-42 and p-tau compared to nonfluent/agrammatic and semantic variants (nfv/svPPA). All nfv/svPPA patients had negative amyloid PET. Among the lvPPA group, a negative amyloid PET was found only in one patient, who was also the only one to display a normal CSF. Thus, this small cohort appeared to display an excellent agreement between CSF and (18)F-florbetapir PET and suggest that these examinations may have the same validity in detecting in vivo evidence of AD pathology in PPA clinical variants.

*Center of Cognitive and Behavioral Disorders

Laboratory of Neuroimmunology, National Neurological Institute, IRCCS C. Mondino Foundation

Department of Neurosciences and Behaviour, University of Pavia

§Nuclear Medicine Unit, ICS Maugeri Spa SB - IRCCS, Pavia, Italy

The authors declare no conflicts of interest.

Reprints: Giulia Perini, MD, National Neurological Institute, IRCCS C. Mondino Foundation, Via Mondino 2, 27100 Pavia, Italy (e-mail: giulia.perini01@universitadipavia.it).

Received May 10, 2018

Accepted October 29, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved